Literature DB >> 31414990

Willingness to Undergo a Risky Treatment to Improve Cognition Among Persons With Cognitive Impairment Who Received an Amyloid PET Scan.

Eric Jutkowitz1,2, Courtney H Van Houtven3,4, Brenda L Plassman5,6, Vincent Mor1,2.   

Abstract

OBJECTIVE: To evaluate determinants of willingness to accept a treatment to return memory to normal among persons with cognitive impairment who received an amyloid positron emission tomography (PET) scan and their care partner and discordance in risk taking.
METHODS: Using data from CARE-IDEAS (n=1872 dyads), a supplement of the Imaging Dementia-Evidence for Amyloid Scanning study, we predicted scan recipient's willingness to accept a risky treatment, the risk care partners believed their care recipient would accept, and discordance in these perceptions.
RESULTS: Scan recipients were willing to accept a treatment with a 27.94% (SD=34.36) risk of death. Care partners believed their care recipient would accept a 29.68% (SD=33.74) risk of death; thus, overestimating risk acceptance by 1.74 (SD=41.88) percentage points. A positive amyloid PET scan was associated with willingness to accept greater risk. Poorer functioning of the care recipient was associated with care partners believing their care recipient would accept more risk. The amyloid PET scan result was not significantly associated with discordance, but poorer functioning of the care recipient resulted in care partners overestimating risk.
CONCLUSIONS: Scan recipients were willing to accept a treatment with a high risk of death. Discordance was affected by scan recipient's having poorer functioning.

Entities:  

Mesh:

Year:  2020        PMID: 31414990      PMCID: PMC7015762          DOI: 10.1097/WAD.0000000000000338

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  29 in total

1.  Do Alzheimer's disease patients want to participate in a treatment decision, and would their caregivers let them?

Authors:  Karen B Hirschman; Colette M Joyce; Bryan D James; Sharon X Xie; Jason H T Karlawish
Journal:  Gerontologist       Date:  2005-06

2.  Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.

Authors:  Arno de Wilde; Wiesje M van der Flier; Wiesje Pelkmans; Femke Bouwman; Jurre Verwer; Colin Groot; Marieke M van Buchem; Marissa Zwan; Rik Ossenkoppele; Maqsood Yaqub; Marleen Kunneman; Ellen M A Smets; Frederik Barkhof; Adriaan A Lammertsma; Andrew Stephens; Erik van Lier; Geert Jan Biessels; Bart N van Berckel; Philip Scheltens
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

3.  Supporting Family Caregivers of Older Americans.

Authors:  Jennifer L Wolff; Judy Feder; Richard Schulz
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

4.  Caregivers' willingness-to-pay for Alzheimer's disease medications in Canada.

Authors:  Mark Oremus; Jean-Eric Tarride; Eleanor Pullenayegum; Natasha Clayton; Gerry Mugford; Marshall Godwin; Allen Huan; Yves Bacher; Juan-Manual Villalpando; Sudeep S Gill; Krista L Lanctôt; Nathan Herrmann; Parminder Raina
Journal:  Dementia (London)       Date:  2013-06-05

5.  Societal and Family Lifetime Cost of Dementia: Implications for Policy.

Authors:  Eric Jutkowitz; Robert L Kane; Joseph E Gaugler; Richard F MacLehose; Bryan Dowd; Karen M Kuntz
Journal:  J Am Geriatr Soc       Date:  2017-08-17       Impact factor: 5.562

6.  Do Family Proxies Get It Right? Concordance in Reports of Nursing Home Residents' Everyday Preferences.

Authors:  Allison R Heid; Lauren R Bangerter; Katherine M Abbott; Kimberly Van Haitsma
Journal:  J Appl Gerontol       Date:  2015-04-28

Review 7.  Shared decision-making in dementia: A review of patient and family carer involvement.

Authors:  Lyndsey M Miller; Carol J Whitlatch; Karen S Lyons
Journal:  Dementia (London)       Date:  2014-11-03

8.  Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy.

Authors:  F Reed Johnson; George Van Houtven; Semra Ozdemir; Steve Hass; Jeff White; Gordon Francis; David W Miller; J Theodore Phillips
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

9.  Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy.

Authors:  F Reed Johnson; Semra Ozdemir; Carol Mansfield; Steven Hass; David W Miller; Corey A Siegel; Bruce E Sands
Journal:  Gastroenterology       Date:  2007-05-03       Impact factor: 22.682

10.  Alzheimer's disease in the NAS-NRC Registry of aging twin veterans, IV. Performance characteristics of a two-stage telephone screening procedure for Alzheimer's dementia.

Authors:  J J Gallo; J C Breitner
Journal:  Psychol Med       Date:  1995-11       Impact factor: 7.723

View more
  2 in total

1.  How Accurately Do Patients and Their Care Partners Report Results of Amyloid-β PET Scans for Alzheimer's Disease Assessment?

Authors:  Hailey J James; Courtney Harold Van Houtven; Steven Lippmann; James R Burke; Megan Shepherd-Banigan; Emmanuelle Belanger; Terrie Fox Wetle; Brenda L Plassman
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

2.  Measurement Properties of the CAPACITY Instrument to Assess Perceived Communication With the Health Care Team Among Care Partners of Patients With Cognitive Impairment.

Authors:  Courtney H Van Houtven; Steven J Lippmann; Emmanuelle Bélanger; Valerie A Smith; Hailey J James; Megan Shepherd-Banigan; Eric Jutkowitz; Emily O'Brien; Jennifer L Wolff; James R Burke; Brenda L Plassman
Journal:  Med Care       Date:  2020-09       Impact factor: 3.178

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.